Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)

Status Not yet recruiting

Clinical Trial Summary

Convalescent plasma has been used for over 100 years in the treatment of severe acute respiratory infections of viral origin. There are not pharmacological treatments for the actual outbreak for SARS-Cov-2 and it is necessary to evaluate the efficacy of treatment options, including convalescent plasma transfusion. The hypothesis is that convalescent plasma is efficacious and safe for reducing mortality in patients with COVID-19 treated in ICU

Clinical Trial Description

Coronavirus infection has been declared by the World Health Organization as a pandemic. In addition to hemodynamic and ventilatory support in the intensive care unit, there is no treatment for COVID-19. Currently proposed treatments (chloroquine, antivirals, immunomodulators, among others) have low quality studies that do not prove efficacy.

Blood or plasma transfusion from convalescent patients (patients who have overcome the disease by generating a competent immune response) has been prescribed for over 100 years. In the last 15 years, convalescent plasma has been studied for the treatment of severe acute respiratory infections of viral origin, such as severe acute respiratory syndrome (SARS), avian influenza, and influenza A (H1N1). Suppressing viremia is one of the possible explanations for the efficacy of convalescent plasma treatment.

For the treatment of COVID-19, there are case series that show a clear improvement in severe patients after administration of convalescent plasma without significant adverse events. At the current crisis of the SARS-CoV-2 pandemic, in which there are no pharmacological treatments that have proven to have any therapeutic effect, it is imperative to assess the efficacy and safety of convalescent plasma transfusion in infected patients.

This is an open, randomized clinical trial with patient allocation in a 2 :1 ratio, plasma: standard management, for a superiority hypothesis. The main objective of this study is to determine the efficacy of convalescent plasma for the treatment of severe COVID-19 infection in terms of decreased in-hospital mortality. ;

Study Design

Related Conditions & MeSH terms

SARS-Cov-2

Clinical Trial Details

NCT number	NCT04391101
Study type	Interventional
Source	Hospital San Vicente Fundación
Contact	Oliver G Perilla Suarez, Hematologist
Phone	+573136395608
Email	gerardoperilla@gmail.com
Status	Not yet recruiting
Phase	Phase 3
Start date	June 2020
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06039449` - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2	Phase 3
Completed	`NCT04512079` - FREEDOM COVID-19 Anticoagulation Strategy	Phase 4
Completed	`NCT04527471` - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT05584202` - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants	Phase 2
Completed	`NCT04579549` - Repeat Testing for SARS-CoV-2	N/A
Active, not recruiting	`NCT05547243` - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China	N/A
Recruiting	`NCT04613310` - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)	N/A
Recruiting	`NCT04747574` - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection	Phase 1
Terminated	`NCT04447404` - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury	Phase 2
Completed	`NCT04515147` - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19	Phase 2
Withdrawn	`NCT04388709` - Interferon Lambda Therapy for COVID-19	Phase 2
Active, not recruiting	`NCT05550142` - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China	N/A
Completed	`NCT04620798` - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students	N/A
Active, not recruiting	`NCT05547256` - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China	N/A
Completed	`NCT04561102` - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed	`NCT04452604` - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed	`NCT05366322` - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed	`NCT04526769` - Detecting SARS-CoV-2 in Tears
Terminated	`NCT04958304` - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed	`NCT04690413` - NOWDx Test for the Detection of Antibodies to COVID-19	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.